Please indicate your specialization * Hematologist Oncologist Oncology Nurse Advanced Practitioner Pharmacist Other, please specify: Please indicate your specialization Other, please specify: What is your preferred method for online learning about recent advances in the management of Hodgkin Lymphoma? * Scientific publications Roundtable/panel discussions by experts in the field Case studies presented by experts in the field Webcasts by experts in the field International congresses highlights Interactive E-learning modules Infographics/visual summaries If you are not able to attend a congress what would be your preferred manner to get updated on the information presented there? * Online written congress reports Online expert roundtable congress reports Local/regional meetings with experts that attended the congress Other, please specify: If you are not able to attend a congress what would be your preferred manner to get updated on the information presented there? Other, please specify: How aware are you of the current and future first-line treatment options for patients with classical Hodgkin Lymphoma? * Very aware Aware Reasonably aware Not very aware Not aware How aware are you of the treatment-related toxicities with standard-of-care treatment for patients with classical Hodgkin Lymphoma? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you of the treatment options after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) for classical Hodgkin Lymphoma? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you of the treatment options for patients with classical Hodgkin Lymphoma with high risk of relapse or progression after stem cell transplantation (auto-HSCT)? * Very aware Aware Reasonably aware Not very aware Not aware How informed are you about the efficacy and safety data of CD30-targeting therapy in patients with classical Hodgkin Lymphoma? * Very well informed Well informed Reasonably informed Poorly informed Not informed How comfortable are you to select and manage patients with classical Hodgkin Lymphoma with CD30-targeting therapy? * Very comfortable Comfortable Reasonably comfortable Not very comfortable Not comfortable How informed are you about the rationale for combining CD30-targeted therapy and immune checkpoint inhibitors in patients with relapsed Hodgkin Lymphoma? * Very well informed Well informed Reasonably informed Poorly informed Not informed How familiar are you with emerging histologic and molecular profiling approaches for determining best management of patients with CD30-positive malignant lymphomas? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
